23.

PATENT APPLICATION ATTORNEY DOCKET 28110/36120C

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No: R. 53(b) continuation of U.S.Ser. No. 09/240,639 filed January 29, 1999 Filed: herewith	Relating to CD39-Like Polypeptides and Nucleic Acids") Group Art Unit: 1644) Examiner: A. Decloux
PRELIMINARY AMENDMENT	
Box Patent Application Commissioner for Patents Washington, DC 20231	
Sir:	
In the claims:	
Please cancel all claims 1-18, without prejudice, and add new claims 19-29 as follows:	
19. An isolated antibody or fragment thereof which specifically binds to a CD39L4	
polypeptide having the amino acid sequence of SEQ ID NO: 6.	
20. The antibody of claim 19 which is a monoclonal antibody.	
21. The antibody fragment of claim	19 which is a fragment of a monoclonal antibody.
22. A hybridoma which produces to	the monoclonal antibody of claim 20.

The antibody of claim 19 which is a polyclonal antibody.

- 24. The antibody fragment of claim 19 which is a fragment of a polyclonal antibody.
- 25. The antibody of claim 19 which comprises a detectable label.
- 26. The antibody of claim 25 wherein the detectable label is a radioisotope, affinity label, enzymatic label, fluorescent label or paramagnetic moiety.
- 27. A method of detecting the presence of a CD39L4 polypeptide having the amino acid sequence of SEQ ID NO: 6 or a fragment thereof in a cell, tissue or fluid sample comprising contacting said cell, tissue or fluid sample with an antibody or fragment of claim 19 under conditions which permit the formation of an antibody/polypeptide complex and detecting the presence of an antibody/polypeptide complex, wherein the presence of the antibody/polypeptide complex indicates the presence of a CD39L4 polypeptide.
- 28. A kit comprising (a) the antibody or antibody fragment of claim 19 and (b) a polypeptide having the amino acid sequence of SEQ ID NO: 6 or an immunologically reactive fragment of said polypeptide.
- 29. A kit comprising (a) the antibody or antibody fragment of claim 19 and (b) a wash reagent or a reagent capable of detecting the presence of a bound antibody.

REMARKS

Support for the claims is found throughout the specification, including at page 80, lines 17-28, page 82, lines 23-27, page 87, lines 23-31 and page 88, lines 23-31. If telephonic discussions with the undersigned would expedite allowance, the Examiner is invited to contact the undersigned at the number below.

Respectfully submitted,

MARSHALL, O'TOOLE, GERSTEIN,

MURRAY & BORUN

Li-Hsien Rin-Laures, M.D.

(312) 474-6300

By:

Registration No. 33,547 6300 Sears Tower 233 South Wacker Drive Chicago, Illinois 60606-6402

July 13, 2001